Mounjaro vs Ozempic: the difference the internet keeps getting wrong

The myth that keeps circulating: "they're basically the same jab"

You'll see it repeated on forums and in videos all the time, that Mounjaro and Ozempic are interchangeable, that one is just the newer version of the other. It's an easy assumption to make and worth putting down gently, because the reality changes what you can and can't get one for.

Mounjaro is Eli Lilly's brand name for tirzepatide. Ozempic is Novo Nordisk's brand name for semaglutide. Two different companies, two different active ingredients. They belong to the same broad group of gut-hormone medicines, which is why they feel similar in conversation, but they are not swaps for each other.

The bigger point is what each is allowed to treat here. Mounjaro holds a UK licence for weight management alongside diet and activity, and separately for type 2 diabetes. Ozempic is licensed in the UK for type 2 diabetes only, not for weight loss, according to the MHRA. That means a UK prescriber cannot legitimately hand out Ozempic as a slimming treatment, even though its active drug, semaglutide, does appear in a weight-loss product under a different brand. If your goal is weight loss, the honest comparison is not really Mounjaro against Ozempic at all, but Mounjaro against the semaglutide product that is licensed for it. More on that below. For a plain rundown of the drug-level distinction, our page on the difference between Mounjaro and Ozempic walks through it without the marketing gloss.

Two receptors versus one: what tirzepatide and semaglutide do inside you

Both medicines lean on the same core idea, copying gut hormones your body releases after eating so that appetite settles and blood sugar behaves. The mechanical difference sits in how many pathways each one touches.

Semaglutide, the drug in Ozempic, is a GLP-1 receptor agonist. It works on a single receptor involved in fullness and glucose control, slowing how quickly the stomach empties so you feel satisfied for longer. Tirzepatide, the drug in Mounjaro, is a dual agonist: it activates both the GLP-1 receptor and a second one, GIP, and it's the only dual-acting weight-management medicine licensed in the UK, per NHS and Diabetes UK information. Whether the second receptor is what drives its results, or simply part of the picture, is still being studied, so it's fair to say the extra pathway matters without over-claiming why.

In practice both are once-weekly injections you can give in the abdomen, thigh or upper arm, rotating the site. Mounjaro comes as a pre-filled KwikPen, with each pen holding four weekly doses. Both start low and step up under a prescriber's direction, because the early weeks are about letting your system adjust rather than chasing an effect. You can read a fuller mechanism breakdown on our tirzepatide versus Ozempic explainer. The NHS medicines guides on tirzepatide and semaglutide set out both profiles in patient-friendly terms if you want the source detail.

A side-by-side look at the two, on the facts that matter

Here's the comparison stripped to what's verifiable. Numbers below come from published UK sources, and a like-for-like weight-loss head-to-head isn't possible for Ozempic because it isn't licensed for that use.

On results, the strongest evidence for tirzepatide in weight management is the SURMOUNT-1 trial, which reported average body-weight reductions of roughly 20 to 21% at the 15mg dose over 72 weeks. That programme involved thousands of adults; SURMOUNT-1 alone randomised 2,539 participants. Because Ozempic sits outside the weight-loss licence, there's no equivalent weight-management trial figure to line up beside it here, which is exactly why comparisons that pit the two on "pounds lost" tend to mislead. NICE's appraisal of tirzepatide (TA1026) covers the evidence the NHS weighed up.

What is actually licensed for weight loss in the UK

If weight loss is the reason you're reading this, the two names that matter are Mounjaro and Wegovy, and Ozempic isn't one of them. Both Mounjaro (tirzepatide) and Wegovy (semaglutide) carry UK weight-management licences for adults with a BMI of 30 or above, or 27 and above with a weight-related condition such as prediabetes, high blood pressure, high cholesterol or obstructive sleep apnoea.

Wegovy is the semaglutide product built for weight loss, so if what drew you to Ozempic was the semaglutide, Wegovy is the legitimate route to that same active drug for this purpose. The practical comparison people usually mean is Mounjaro against Wegovy, and we've laid that out in detail on our Wegovy versus Mounjaro for weight loss page and, at the drug level, on tirzepatide versus semaglutide.

There's now also an oral option: in June 2026 the MHRA approved a semaglutide tablet for weight management, a first for the UK. So the licensed picture for weight loss is broader than a single injection. What none of it includes is Ozempic, and any UK seller offering Ozempic "for weight loss" is stepping outside its licence. nume dispenses Mounjaro and Wegovy for weight management through our own GPhC-registered pharmacy, and never Ozempic for that use. If you're weighing the two licensed injections, is Mounjaro better than Wegovy tackles the question people ask most.

Eligibility: who a prescriber can actually consider

Meeting a BMI number is the start of the conversation, not the end of it. For the licensed weight-management medicines, a prescriber looks at whether you're an adult with a BMI of 30 or more, or 27 or more alongside a weight-related health condition. Those thresholds can sit 2.5 kg/m² lower for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, reflecting UK guidance on how weight-related risk varies.

A few groups aren't suitable regardless of BMI. These medicines aren't licensed for under-18s, and they aren't recommended if you're pregnant, breastfeeding or trying for a baby. A history of medullary thyroid cancer, MEN2, pancreatitis or certain gut conditions needs an honest discussion with the prescriber before anything is considered. None of this is box-ticking; it's the difference between a medicine being appropriate and being risky for you specifically.

One practical detail worth flagging early: with tirzepatide, women using the contraceptive pill are advised to add a non-oral method, such as condoms, for the first four weeks of treatment and for four weeks after each dose increase, because the pill's absorption may be reduced. NHS guidance notes no equivalent evidence of that effect with semaglutide. That's the sort of thing our prescribers raise at consultation rather than leave you to find out later. You can check the practical route and where you'd stand on our weight-loss treatment overview, and the NHS BMI calculator is a sensible first step before you speak to anyone.

Side effects: what the two share, and when to seek help

The side-effect stories tend to overlap because both medicines act on the same gut-hormone system. Most of what people notice is digestive: feeling sick, being sick, loose stools or constipation, indigestion, burping, sometimes fatigue, headache or dizziness. These are usually at their most obvious in the first days after starting or after a dose goes up, and for many people they ease within a couple of weeks as the body adjusts. Injection-site reactions can happen too.

There's a serious but uncommon risk worth naming plainly. In January 2026 the MHRA issued a Drug Safety Update flagging acute pancreatitis as a known, infrequent side effect of GLP-1 medicines that can be serious. The signal to act on is severe, persistent stomach pain that may spread through to your back, with or without vomiting. That warrants urgent medical help, not a wait-and-see. Other reasons to get seen promptly include signs of gallbladder trouble, dehydration from severe sickness or diarrhoea, an allergic reaction, or sudden changes in vision.

If you're prescribed either drug and suspect a side effect, you can report it through the MHRA's Yellow Card scheme, which also collects reports about suspect sellers. None of this is meant to frighten you off; it's the ordinary reality of a potent medicine, and it's why supervision matters more than a low price. Our aftercare runs seven days a week for exactly these moments, so a worried question on a Sunday doesn't have to wait until Monday.

NHS versus private, and where cost really sits

On the NHS, access to weight-management medicines is deliberately narrow and rolling out in phases. Tirzepatide provision under NICE TA1026 currently reaches adults with the highest BMI and several qualifying conditions, widening gradually over the coming years, and from April 2026 some GP practices can prescribe it, though participation is optional and varies by area. Everyone on the NHS route takes part in wrap-around diet and activity support, and meeting the criteria doesn't guarantee a prescription. Wegovy on the NHS runs through specialist weight-management services under TA875, where waiting lists are often long. NHS England's page on weight-management injections sets out the current position.

If you don't meet those criteria, or don't want to wait, a regulated private pharmacy is the alternative. On cost, private weight-loss treatment is priced per month and varies by dose and provider; since Eli Lilly raised Mounjaro's UK list price from September 2025, reported private prices typically range from around £149 to £375 a month. Ozempic sits outside this entirely, being a diabetes medicine, so pricing it "for weight loss" doesn't apply.

We're upfront that nume isn't the cheapest, and that's a choice. One transparent price covers the consultation, the prescription, next-working-day tracked delivery and seven-day aftercare, with no subscription and every repeat clinically re-reviewed. For a prescription medicine, the lowest listing answers the wrong question anyway; genuine supply and real supervision are what keep you safe.

Related questions we've answered

• Is Ozempic or Mounjaro better?
• Switching from Ozempic to Mounjaro
• The difference between Mounjaro and Wegovy
• Wegovy or Mounjaro for weight loss?